|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Radboud University |
|---|---|
| Information provided by: | Radboud University |
| ClinicalTrials.gov Identifier: | NCT00184938 |
Purpose
The most powerful protective mechanism against ischemia-reperfusion injury other than rapid reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size. This mechanism can be mimicked by several pharmacological substances such as adenosine and morphine.
We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a method in which we can detect ischemia-reperfusion injury in the human forearm by using Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic ischemic preconditioning and that acute ischemic preconditioning can be blocked with the opioid receptor antagonist naloxon. This study will increase our knowledge about the mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous protective mechanism in a clinical setting.
| Condition | Intervention |
|---|---|
|
Ischemia-Reperfusion Injury |
Drug: morphine Drug: naloxone Drug: Technetium-TC99m-labeled Annexin A5 Procedure: forearm ischemic exercise Procedure: ten minute forearm ischemia |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double-Blind |
| Official Title: | Opioid Induced Acute Preconditioning |
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands | |
| Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology | |
| Nijmegen, Gelderland, Netherlands, 6500 HB | |
| Principal Investigator: | Gerard Rongen, MD, Phd | Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology |
More Information
| ClinicalTrials.gov Identifier: | NCT00184938 History of Changes |
| Other Study ID Numbers: | OPIRI |
| Study First Received: | September 12, 2005 |
| Last Updated: | March 27, 2008 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
opioids ischemic preconditioning morphine |
|
Ischemia Reperfusion Injury Pathologic Processes Vascular Diseases Cardiovascular Diseases Postoperative Complications Morphine Analgesics, Opioid Naloxone Annexin A5 Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotics Narcotic Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |